The validity of the SF-12 and SF-6D instruments in people living with HIV/AIDS in Kenya

Table 2 Mean HRQoL scores by severity subgroup

Sub Group	PCS (SD^a)	MCS (SD^a)	SF6D (SD^a)
CD4 < 200 N = 364	41.1 (11.0)^*	43.4 (10.7)^*	0.67(0.15)^*
CD4 ≥ 200 N = 169	45.4 (10.3)^*	45.8 (11.0)^*	0.72(0.15)^*
Viral Load >55,000 N = 281	41.5 (10.6)^*	43.8 (10.9)	0.67 (0.15)^*
Viral Load ≤55,000 N = 214	43.7 (11.3)^*	44.5 (10.8)	0.71 (0.16)^*
WHO Stage 1 N = 114	46.7 (8.7)^**	46.0 (11.0)^**	0.73 (0.15)^**
WHO Stage 2 N = 126	44.7 (10.3)	44.6 (10.3)	0.71 (0.15)
WHO Stage 3 N = 204	39.5 (11.3)^**	42.7 (11.0)	0.66 (0.16)^**
WHO Stage 4 N = 22	36.9 (11.3)^**	41.6 (10.2)^**	0.61 (0.13)^**

^aStandard Deviation
*Statistically significant difference between severity group p < 0.05
**Statistically significant difference between severity group p < 0.05 based on ANOVA with post-hoc Tukey’s procedure

ISSN: 1477-7525